Business
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
PASADENA, Calif., January 06, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the "notes") and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $75 milli
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1609,"height":335,"url":"https://media.zenfs.com/en/business-wire.com/7c1a07e342ec30d45a524aa936524cd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6aaLdFdRL9CH.wIPbNhMDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7c1a07e342ec30d45a524aa936524cd2","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/mubx421GrBoxcVaMgMbg9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7c1a07e342ec30d45a524aa936524cd2","width":1200,"height":250}},"lazy":false},{"type":"text","content":"PASADENA, Calif., January 06, 2026--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the "notes") and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes solely to cover over-allotments and expects to grant the underwriters of the common stock offering a 30-day option to purchase up to an additional $30 million of common stock. The completion of the note offering will not be contingent on the completion of the common stock offering, and the completion of the common stock offering will not be contingent on the completion of the note offering.","length":959,"tagName":"p"},{"type":"text","content":"J.P. Morgan and Jefferies are acting as joint book-running managers for the note offering, and Jefferies and J.P. Morgan are acting as joint book-running managers for the common stock offering.","length":193,"tagName":"p"},{"type":"text","content":"The notes will be senior, unsecured obligations of Arrowhead, will accrue interest payable semi-annually in arrears and will mature on January 15, 2032, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Arrowhead will settle conversions by paying or d...